Cardinal Health completes sale of Cordis business to Hellman & Friedman


Cardinal HealthCardinal Health and Hellman & Friedman (H&F) have revealed the completion of the previously announced sale of Cardinal Health’s Cordis business to H&F. The sale price of approximately US$1 billion includes the buyer’s assumption of certain liabilities and the seller’s retention of certain working capital accounts.

“We appreciate H&F’s partnership throughout the transaction, and we are excited about Cordis’s future under H&F’s ownership,” said Mike Kaufmann, CEO of Cardinal Health. “As we shared previously, this divestiture demonstrates our disciplined portfolio evaluation approach, and we remain committed to investing in our strategic growth areas.”

“We are thrilled to begin this next chapter for Cordis and value the partnership with Cardinal Health through the transition,” said Shar Matin, CEO of Cordis. “We believe that an independent Cordis company, combined with an innovative approach to bring differentiated products to market, will allow us to create incremental value for teammates, customers and investors.”

Cardinal Health plans to release its fourth-quarter and year-end financial results for its fiscal year 2021 on 5 August prior to the opening of trading on the New York Stock Exchange.


Please enter your comment!
Please enter your name here